Departments of Medicine.
Gastroenterology and Hepatology, California Pacific Medical Center, San Francisco.
J Clin Gastroenterol. 2020 Aug;54(7):e63-e72. doi: 10.1097/MCG.0000000000001204.
The goal of this study was to evaluate disparities in hospital outcomes among inflammatory bowel disease (IBD) related hospitalizations in the United States with a focus on ethnicity-specific disparities.
IBD-related hospitalizations contribute to significant morbidity and health care economic burden.
IBD-related hospitalizations (identified with ICD-9) among US adults were evaluated using 2007 to 2013 Nationwide Inpatient Sample. In-hospital mortality between groups was evaluated using χ and multivariate logistic regression models, stratified by Crohn's disease (CD) and ulcerative colitis (UC). Inflation-adjusted total hospitalization charges were evaluated using Student t test and multivariate linear regression.
Among 224,500 IBD-related hospitalizations (77.8% CD, 22.2% UC), overall in-hospital mortality was low (0.99% CD, 0.78% UC). Although Hispanic UC patients had a trend towards higher odds of in-hospital mortality compared with non-Hispanic whites (OR, 1.54; 95% CI, 0.95-2.51; P=0.08), no ethnicity-specific disparities were observed in CD. From 2007 to 2013, mean inflation-adjusted hospitalization charges increased from $29,632 to $41,484, P<0.01 in CD and from $31,449 to $43,128 in UC, P<0.01. On multivariate regression, hospitalization charges in Hispanic CD patients were $9302 higher (95% CI, 7910-10,694; P<0.01) and in Asian CD patients were $7665 higher (95% CI, 4859-10,451; P<0.001) than non-Hispanic whites. Compared with non-Hispanic white UC patients, Hispanics had $6910 (95% CI, $4623-$9197) higher charges and African Americans had $3551 lower charges (95% CI, -$5002 to -$2101).
Although most IBD hospitalizations in the United States were among non-Hispanic whites, Hispanic patients with IBD had a trend towards higher in-hospital mortality and contributed to significantly higher hospitalization charges.
本研究旨在评估美国炎症性肠病(IBD)相关住院治疗中存在的医院结局差异,并重点关注特定种族的差异。
IBD 相关住院治疗会导致严重的发病率和医疗保健经济负担。
使用 2007 年至 2013 年全美住院患者样本,评估美国成年人的 IBD 相关住院治疗(通过 ICD-9 确定)。通过 χ 检验和多变量逻辑回归模型,按克罗恩病(CD)和溃疡性结肠炎(UC)分层,评估组间住院死亡率。使用学生 t 检验和多变量线性回归评估调整通货膨胀后的总住院费用。
在 224500 例 IBD 相关住院治疗中(77.8% CD,22.2% UC),总体院内死亡率较低(0.99% CD,0.78% UC)。尽管西班牙裔 UC 患者的住院死亡率与非西班牙裔白人相比有较高的趋势(OR,1.54;95%CI,0.95-2.51;P=0.08),但在 CD 中未观察到特定种族的差异。从 2007 年到 2013 年,调整通货膨胀后的平均住院费用从 CD 中的 29632 美元增加到 41484 美元,P<0.01,UC 中的从 31449 美元增加到 43128 美元,P<0.01。在多变量回归中,西班牙裔 CD 患者的住院费用比非西班牙裔白人高 9302 美元(95%CI,7910-10694;P<0.01),亚裔 CD 患者的住院费用高 7665 美元(95%CI,4859-10451;P<0.001)。与非西班牙裔白人 UC 患者相比,西班牙裔患者的费用高出 6910 美元(95%CI,4623-9197),而非裔美国人的费用则低 3551 美元(95%CI,-5002 美元至-2101 美元)。
尽管美国大多数 IBD 住院治疗都发生在非西班牙裔白人中,但患有 IBD 的西班牙裔患者的住院死亡率呈上升趋势,并且导致住院费用显著增加。